COVID-19: A Personalized Cardiometabolic Approach for Reducing Complications and Costs. The Role of Aging beyond Topics

Sabán-Ruiz, J.; Ly-Pen, D

doi:10.1007/s12603-020-1385-5

Cited by 12 publications

(13 citation statements)

References 86 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, it was illustrated that SARS-CoV-2 infection in T2DM patients augments the risk of AIS through the provocation of underlying cardio-metabolic disturbances, as reported by Zaki et al ( 20 ). Most recruited patients had a positive family history of stroke, smoking, hypertension, T2DM, and dyslipidemia that increased the risk of AIS during the development of COVID-19, as confirmed by Saban-Ruiz et al ( 21 ). Correspondingly, it has been shown that the risk of AIS during COVID-19 is approximately 5%, with 65.6% of AIS in COVDI-19 patients being labeled as cryptogenic stroke.…”

Section: Discussionmentioning

confidence: 58%

COVID-19 and Risk of Acute Ischemic Stroke and Acute Lung Injury in Patients With Type II Diabetes Mellitus: The Anti-inflammatory Role of Metformin

et al. 2021

View full text Add to dashboard Cite

Background: Coronavirus disease 19 (COVID-19) is regarded as an independent risk factor for acute ischemic stroke (AIS) due to the induction of endothelial dysfunction, coagulopathy, cytokine storm, and plaque instability.Method: In this retrospective cohort study, a total of 42 COVID-19 patients with type 2 diabetes mellitus (T2DM) who presented with AIS within 1 week of displaying COVID-19 symptoms were recruited. According to the current anti-DM pharmacotherapy, patients were divided into two groups: a Metformin group of T2DM patients with COVID-19 and AIS on metformin therapy (850 mg, 3 times daily (n = 22), and a Non-metformin group of T2DM patients with COVID-19 and AIS under another anti-DM pharmacotherapy like glibenclamide and pioglitazone (n = 20). Anthropometric, biochemical, and radiological data were evaluated.Results: Ferritin serum level was lower in metformin-treated patients compared to non-metformin treated patients (365.93 ± 17.41 vs. 475.92 ± 22.78 ng/mL, p = 0.0001). CRP, LDH, and D-dimer serum levels were also lowered in metformin-treated patients compared to non-metformin treated patients (p = 0.0001). In addition, lung CT scan scores of COVID-19 patients was 30.62 ± 10.64 for metformin and 36.31 ± 5.03 for non-metformin treated patients.Conclusion: Metformin therapy in T2DM patients was linked to a lower risk of AIS during COVID-19. Further studies are needed to observe the link between AIS in COVID-19 diabetic patients and metformin therapy.

show abstract

Section: Discussionmentioning

confidence: 58%

COVID-19 and Risk of Acute Ischemic Stroke and Acute Lung Injury in Patients With Type II Diabetes Mellitus: The Anti-inflammatory Role of Metformin

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In patients with heart failure, appropriate medications, including RASi , should be considered [ 61 ]. The risk/benefit of statin use is still controversial in patients affected by COVID-19, except for patients with diabetes, history of stroke or CHD , and familial hypercholesterolemia [ 71 , 72 ]. However, a molecular docking study has suggested that statins may act as SARS-CoV-2 Mpro inhibitors (a protein of the viral envelope); clinical investigations are needed to clarify whether statins could exert beneficial effects in the treatment of COVID-19 [ 73 ].…”

Section: Therapeutic Implicationsmentioning

confidence: 99%

Cardiovascular involvement during COVID-19 and clinical implications in elderly patients. A review

Napoli

Tritto

Benincasa

et al. 2020

Annals of Medicine and Surgery

View full text Add to dashboard Cite

SARS-CoV-2 betacoronavirus is responsible for the Corona Virus Disease 2019 (COVID-19) which has relevant pathogenic implications for the cardiovascular system. Incidence and severity of COVID-19 are higher in the elderly population (65 years and older). This may be due to higher frequency of comorbidities, but increased frailty and immunosenescence linked with aging may also contribute. Moreover, in elderly individuals, SARS-CoV-2 may adopt different molecular strategies to strongly impact on cardiac aging that culminate in exacerbating a pro-inflammatory state (cytokine storm activation), which, in turn, may lead to pulmonary vascular endothelialitis, microangiopathy, diffuse thrombosis, myocarditis, heart failure, cardiac arrhythmias, and acute coronary syndromes. All these events are particularly relevant in elderly patients, and deserve targeted cardiovascular treatments and specific management of repurposed drugs against COVID-19. We discuss current evidence about the cardiovascular involvement during COVID-19, and elaborate on clinical implications in elderly patients.

show abstract

“…This suggests that the pancreas can also be attacked and damaged by SARS-CoV-2. This damage to pancreatic islet cells leads to abnormal insulin secretion, exacerbates the endocrine disorder in patients, and aggravates the damage to other organs [97]. COVID-19 may further lead to organ and tissue dysfunction because of the increased risk of cardiovascular disease and stroke resulting from diabetic nephropathy and diabetes [98].…”

Section: Diabetes In the Elderly And Susceptibility To Covid-19mentioning

confidence: 99%

Influence of aging on deterioration of patients with COVID-19

Pang

Liu

Shen³

et al. 2020

Aging

View full text Add to dashboard Cite

Aging is an important factor affecting the deterioration of patients with coronavirus disease 2019 (COVID-19). The aging and degeneration of various tissues and organs in the elderly lead to impaired organ function. Underlying conditions such as chronic lung disease, cardiovascular disease, and diabetes in aged patients are associated with higher mortality. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily interacts with the cell surface receptor angiotensin-converting enzyme (ACE) 2 and other accessory proteins such as 78 kDa glucoseregulated protein 78 (GRP78) and CD147. Thus, altered receptor signals in aging and chronic disease play a role in SARS-CoV-2 infection, and are associated with a higher risk of deterioration in different organs. In this review, after a brief introduction to the link between aging and receptors for SARS-CoV-2, we focus on the risk of deterioration in different organs of COVID-19 patients considering aging as the main factor. We further discuss the structural and/or physiological changes in the immune system and organs (lung, heart, kidney, vessels, nerve system), as well as those associated with diabetes, in aging patients, and speculate on the most likely mechanisms underlying the deterioration of COVID-19 patients.

show abstract

COVID-19: A Personalized Cardiometabolic Approach for Reducing Complications and Costs. The Role of Aging beyond Topics

Cited by 12 publications

References 86 publications

COVID-19 and Risk of Acute Ischemic Stroke and Acute Lung Injury in Patients With Type II Diabetes Mellitus: The Anti-inflammatory Role of Metformin

COVID-19 and Risk of Acute Ischemic Stroke and Acute Lung Injury in Patients With Type II Diabetes Mellitus: The Anti-inflammatory Role of Metformin

Cardiovascular involvement during COVID-19 and clinical implications in elderly patients. A review

Influence of aging on deterioration of patients with COVID-19

Contact Info

Product

Resources

About